1-3 of 3
Beatriz F Ribeiro
Close
Sort by
Journal Articles

Early Molecular Response Is Predictive Of Overall, Progression-Free and Event-Free Survival In Chronic Myeloid Leukemia Using Second-Generation Tyrosine Kinase Inhibitors After Imatinib Treatment

Beatriz F Ribeiro, Bruna Vergilio, Eliana C M Miranda, MEd, Maria Helena Almeida, RN, Marcia Torresan Delamain, MD, Rosana A Silveira, MSc, Carmino A De Souza, Sr., MD, PhD, Dulcinéia Martins Albuquerque, BSc, MSc, PhD, Andrey dos Santos, PhD, Irene Lorand-Metze, MD, PhD, Vagner O Duarte, Gislaine O. Duarte, PhD, Katia B. Pagnano, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1326.
https://doi.org/10.1182/blood.V122.21.1326.1326
Published: 2013
Journal Articles

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Beatriz F Ribeiro, Eliana C M Miranda, MEd, Marcia T Delamain, MD, Gislaine Borba Oliveira, MD,, Maria Helena Almeida, RN, Vagner O Duarte, Irene L Metze, MD, PhD, Carmino A De Souza, Sr., MD, PhD, Rosana A Silveira, Katia B. Pagnano, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 5189.
https://doi.org/10.1182/blood.V122.21.5189.5189
Published: 2013
Journal Articles

Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses

Katia B. Pagnano, MD, Beatriz F Ribeiro, Eliana C M Miranda, Marcia T Delamain, MD, Carmino Antonio De Souza, PhD, Gislaine O Duarte, MD, Bruna Vergilio, Dulcinéia Martins Albuquerque, BSc, MSc, PhD, Andrey dos Santos, PhD, Anderson Tavares, Irene Lorand-Metze, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3787.
https://doi.org/10.1182/blood.V120.21.3787.3787
Published: 2012